| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a8470f22066c0ba2fe50741174c7ab |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 |
| filingDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e352f61192d0fdf438d7f86ec8a8d3f7 |
| publicationDate |
2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021330613-A1 |
| titleOfInvention |
Dosage forms and methods for enantiomerically enriched or pure bupropion |
| abstract |
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11433035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786488-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344513-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344514-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660273-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11660274-B2 |
| priorityDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |